Technical validation of quantitative methods for 3 'deoxy-3-[18F] fluorothymidine ([18F] FLT) PET in liver metastases of colorectal cancer patients
Completed
- Conditions
- Colorectal liver metastasismetastasis of gut cancer in the liver10027476
- Registration Number
- NL-OMON41755
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 5
Inclusion Criteria
Patient age 18 years or older
Histological diagnosis of mCRC (stage IV) without options for localregional treatment
Presence of liver metastases on CT scan
Presence of at least one liver metastases of >20mm in diameter on the CT scan
Upper part of liver with left heart ventricle in field of view
Able to remain supine for 90 minutes in the PET-CT scanner
Ability to give study specific written informed consent
Exclusion Criteria
Pregnant or lactating patients (positive pregnancy test)
Metal implants (eg pacemakers)
Body weight > 100 kg
Severe claustrophobia
Receiving chemotherapy less than 2 months prior to the first PET scan, except in the case of progression under chemotherapy than a 2 week interval is required.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The proportion of number of concordant lesion observed with both [18F] FLTPET<br /><br>and CT scans on the total number of lesions observed with the CT scan<br /><br>(qualitative assessment).</p><br>
- Secondary Outcome Measures
Name Time Method <p>1. Measurements per lesion from full kinetic filtering model<br /><br>2. Measurements per lesion from simplified models<br /><br>3.Test-retest reproducibility of each quantitative assessment of tumor [18F]<br /><br>FLT uptake<br /><br>4. Correlation of full kinetic modeling with more simplified model per lesion</p><br>